07:48 AM EDT, 10/22/2026 (MT Newswires) -- BioNTech (22UA.F) and US biopharmaceutical company Gilead Sciences (GIS.F) entered a clinical trial partnership and supply agreement to evaluate a drug combination for advanced triple-negative breast cancer. The phase 3 Rosetta Breast-01 study will test the German biopharmaceutical company's pumitamig investigative drug alongside Gilead's targeted cancer therapy Trodelvy, according to a Thursday release. The trial will focus on patients with locally advanced or metastatic PD-L1 low or negative triple-negative breast cancer. BioNTech and its development partner Bristol Myers Squibb plan to replace chemotherapy with Trodelvy in the trial, pending regulatory approval. Gilead will supply the drug for the study.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.